**Supplementary Table 2.** Patient disposition

|  |  |
| --- | --- |
| **Disposition** | **Vemurafenib(n=172)** |
| Study disposition, No. (%) |  |
| Patient discontinued | 172 (100) |
| Patient ongoing | 0 |
| Patient completed | 0 |
| Reason for study discontinuation, No. (%) |  |
| Death | 83 (48) |
| Lost to follow-up | 9 (5) |
| Withdrawal by patient | 33 (19) |
| Other | 47 (27) |
| Median time to study discontinuation, months (range) | 10.7 (0.1–46.3) |
| Vemurafenib disposition, No. (%) |  |
| Discontinued vemurafenib | 172 (100) |
| Ongoing | 0 |
| Completed treatment | 0 |
| Reason for vemurafenib discontinuation, No. (%) |  |
| Progressive disease | 105 (61.0) |
| Adverse event | 20 (11.6) |
| Death | 5 (2.9) |
| Withdrawal by patient | 13 (7.6) |
| Physician decision | 6 (3.5) |
| Other | 23 (13.4) |
| Median time to vemurafenib discontinuation, months (range) | 5.6 (0–44.2) |